Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | PMM2 | O15305 | 2/20 | 0.35 |
| ▸ | G6PD | P11413 | 2/20 | 0.35 |
| ▸ | MPI | P34949 | 2/20 | 0.35 |
| ▸ | PHOSPHO1 | Q8TCT1 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304069 | 0.87 | HSD17B10 (0.46) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL3300942 | 0.79 | ALDH1A1 (0.58) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL147877 | 0.75 | ALDH1A1 (0.67) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL3301694 | 0.75 | ALDH1A1 (0.56) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL3302789 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Fluorofenidone SCHEMBL1047536 | 0.73 | ALDH1A1 (0.64) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL3306043 | 0.73 | KDM4E (0.50) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| Fluorofenidone SCHEMBL29420525 | 0.73 | ALDH1A1 (0.64) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL16474668 | 0.72 | ALDH1A1 (0.58) | KDM4EALDH1A1CYP1A2HPGDBLM | |
| SCHEMBL10025187 | 0.72 | KDM4E (0.74) | KDM4EALDH1A1CYP1A2HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | claimed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | claimed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | claimed |
| EP-1878428-A1 | 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES | Xiangya Hospital of Central South University (CN) | 2008-01-16 | — | — | EP | claimed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | claimed |
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | DIEREPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | TAO LI JIAN | 2009-10-15 | — | — | US | disclosed |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2009-01-01 | — | — | US | disclosed |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI JIAN | 2008-12-25 | — | — | US | disclosed |
| EP-1878428-A1 | 1-(SUBSTITUTED PHENYL)-5- METHYL- 2 - (1H) PYRIDONE IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING FIBROSIS IN ORGANS OR TISSUES | Xiangya Hospital of Central South University (CN) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | TAO LI J | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099719-A1 | COMPOSITION AND METHOD FOR TREATING PROTEINURIA | REN, PTPRF, PPM1F | KDM4E 280/4885ALDH1A1 341/4885CYP1A2 837/4885 |
| US-20090005424-A9 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885 |
| US-20080319027-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885 |
| US-20090258911-A1 | COMPOSITION AND METHOD FOR TREATING FIBROTIC DISEASES | COL1A1, COL2A1, MMP1 | KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885 |
| US-20070203203-A1 | Composition and Method for Treating Fibrotic Diseases | COL1A1, COL2A1, MMP1 | KDM4E 317/4885ALDH1A1 485/4885CYP1A2 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.